Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-604-2704344
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Neovasc (TSE:NVC) Frequently Asked Questions
What is Neovasc's stock symbol?
Neovasc trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVC."
How were Neovasc's earnings last quarter?
Neovasc Inc. (TSE:NVC) issued its earnings results on Wednesday, November, 14th. The company reported ($0.80) EPS for the quarter. The firm earned $0.63 million during the quarter, compared to the consensus estimate of $0.60 million. View Neovasc's Earnings History.
When is Neovasc's next earnings date?
Has Neovasc been receiving favorable news coverage?
Press coverage about NVC stock has been trending somewhat negative on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neovasc earned a news impact score of -1.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Paul L. Geyer, Independent Chairman of the Board
- Fred Colen, President, Chief Executive Officer
- Christopher Clark, Chief Financial Officer, Corporate Secretary
- Brian McPherson, Chief Operating Officer
- Vicki Lee Bebeau, Vice President - Clinical Affairs
- Randy Lane, Vice President - Research & Development
- Alexei J. Marko, Director
- Jane H. Hsiao Ph.D., Independent Director (Age 69)
- Douglas Glen Janzen, Independent Director
- William O'Neill, Independent Director (Age 61)
How do I buy shares of Neovasc?
Shares of NVC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Neovasc's official website?
How can I contact Neovasc?
Neovasc's mailing address is 13562 Maycrest Way Suite 5138, RICHMOND, BC V6V 2J7, Canada. The company can be reached via phone at +1-604-2704344.
MarketBeat Community Rating for Neovasc (TSE NVC)
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
